The ROE as of September 2024 (TTM) for Gossamer Bio, Inc. (GOSS) is -117.33%

According to Gossamer Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -117.33%. This represents a change of 121.94% compared to the average of -52.87% of the last 4 quarters.

Gossamer Bio, Inc. (GOSS) Historical ROE (quarterly & annually)

How has GOSS ROE performed in the past?

The mean historical ROE of Gossamer Bio, Inc. over the last ten years is 19.21%. The current -117.33% ROE has changed -710.62% with respect to the historical average. Over the past ten years (40 quarters), GOSS's ROE was at its highest in in the March 2018 quarter at 379.44%. The ROE was at its lowest in in the March 2022 quarter at -203.01%.

Gossamer Bio, Inc. (GOSS) ROE by Quarter and Year

Discovering the peaks and valleys of Gossamer Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Gossamer Bio, Inc. (GOSS) Average ROE

How has GOSS ROE performed in the past?

The current ROE of Gossamer Bio, Inc. (GOSS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Gossamer Bio, Inc. (GOSS) ROE vs. Peers

How is GOSS’s ROE compared to its peers?

Gossamer Bio, Inc.’s ROE is greater than Biomea Fusion, Inc. (-91.86%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Akero Therapeutics, Inc. (-29.56%), greater than Homology Medicines, Inc. (-100.91%), greater than Replimune Group, Inc. (-52.15%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Kronos Bio, Inc. (-68.82%), greater than Passage Bio, Inc. (-70.73%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than TCR2 Therapeutics Inc. (-89.51%), greater than Harpoon Therapeutics, Inc. (-904.27%), greater than Alector, Inc. (-102.63%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Atreca, Inc. (-195.22%), greater than 4D Molecular Therapeutics, Inc. (-24.06%),

Build a custom stock screener for Gossamer Bio, Inc. (GOSS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gossamer Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gossamer Bio, Inc. (GOSS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gossamer Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.